Recent News
Patients with Mesothelioma Don’t Always Have Access to the Best Care
Unfortunately, there is a lack of equality when it comes to treating mesothelioma patients because access to care can be very inconsistent. Patients might not have access to a high-volume…
A Cancer Fighting Gel Can Help Mesothelioma Patients
A cancer fighting gel that is applied directly to tumors could help mesothelioma patients. Researchers in Maryland tested the treatment on animals with mesothelioma tumors. The tumors responded even after…
MRIs vs CT Scans for Imaging Mesothelioma
MRI scans could be better than CT scans for diagnosing and monitoring disease response in pleural mesothelioma patients. An Italian study is looking at the two imaging techniques to compare…
Ramucirumab and Gemcitabine are Showing Promising Results as a Second Line Treatment for Pleural Mesothelioma
Combining the drug ramucirumab with the chemotherapy drug gemcitabine is showing to be a successful second line treatment for pleural mesothelioma. Ramucirumab is a type of immunotherapy drug called a…
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
Primary Outcome Measures Major Pathologic (Disease) Response of Tumor to Nivolumab Combined with Ipilimumab Before Surgery [ Time Frame: 24 months ] The response of participant’s tumor to treatment with nivolumab and ipilimumab before…
Mesothelioma Patient Health Improves a Year After Surgery
It could take time for mesothelioma patients to have better lung function after pleural mesothelioma surgery since some patients have better lung function a year after surgery compared to the…
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
Primary Outcome Measures Response rate [ Time Frame: Up to 4 years after study activation ] Will be compared between arms. Secondary Outcome Measures Major pathologic response rate [ Time Frame: Up to 3 years ] The proportion…
Tremelimumab and Durvalumab are a Good Second Line Treatment for Mesothelioma
Two immunotherapy drugs, tremelimumab and durvalumab, are showing to be a successful second line treatment for pleural mesothelioma when combined. This could mean that more treatments will be approved for…
Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso) (AtezoMeso)
Primary Outcome Measures To evaluate the efficacy of atezolizumab in patients with MPM in terms of DFS [ Time Frame: 12 weeks ] DFS, defined as the time from initiation of study treatment to…
HITHOC After Pleurectomy and Decortication Surgery Can Improve Survival
There are some good results coming from a German study looking at Pleurectomy and Decortication surgery (P/D) being combined with HITHOC. Pleurectomy surgery is surgery that removes mesothelioma tumors but…
